PCSK9 and familial hypercholesterolemia: Clinical studies have shown that circulating ApoB served as an independent predictor of renal replacement therapy in DKD patients (12, 13), and PCSK9 can promote hypercholesterolemia, and PCSK9 concentrations were associated with chronic kidney disease stages (14) and lipid-lowering regimens (15).